Literature DB >> 21516413

Cell sensitivity assays: the ATP-based tumor chemosensitivity assay.

Sharon Glaysher1, Ian A Cree.   

Abstract

The ATP-based tumor chemosensitivity assay (ATP-TCA) is a standardised system which can be adapted to a variety of uses with both cell lines and primary cell cultures. It has a strong track record in drug development, mechanistic studies of chemoresistance and as an aid to clinical decision-making. The method starts with the extraction of cells in suspension from continuous cell culture (for cell lines), malignant effusions or biopsy material. Enzymatic digestion is used to obtain cells from tumor tissue. The assay uses a serum-free medium and polypropylene plates to prevent the growth of non-neoplastic cells over a 6-day incubation period followed by detergent-based extraction of cellular ATP for measurement by luciferin-luciferase assay in a luminometer. The assay results are usually shown as percentage inhibition at each concentration tested, and can be used with suitable software to examine synergy between different anticancer agents.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21516413     DOI: 10.1007/978-1-61779-080-5_21

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  9 in total

1.  Heterogeneity of chemosensitivity in esophageal cancer using ATP-tumor chemosensitivity assay.

Authors:  Zhi-qiang Ling; Chun-jian Qi; Xiao-xiao Lu; Li-juan Qian; Lin-hui Gu; Zhi-guo Zheng; Qiang Zhao; Shi Wang; Xian-hua Fang; Zhi-xing Yang; Jian Yin; Wei-min Mao
Journal:  Acta Pharmacol Sin       Date:  2012-01-30       Impact factor: 6.150

2.  Heterogeneity of tumor chemosensitivity in ovarian epithelial cancer revealed using the adenosine triphosphate-tumor chemosensitivity assay.

Authors:  Jin Zhang; Hongxia Li
Journal:  Oncol Lett       Date:  2015-03-18       Impact factor: 2.967

3.  Enhanced RegIV expression predicts the intrinsic 5-fluorouracil (5-FU) resistance in advanced gastric cancer.

Authors:  Li-Sha Ying; Jiang-Liu Yu; Xiao-Xiao Lu; Zhi-Qiang Ling
Journal:  Dig Dis Sci       Date:  2012-09-26       Impact factor: 3.199

4.  A retrospective study of the correlation of in vitro chemosensitivity using ATP-TCA with patient clinical outcomes in acute myeloid leukemia.

Authors:  Fan Xia; Sheng Ma; Yicong Bian; Di Yu; WenXia Ma; Miao Miao; Chenrong Huang; Liyan Miao
Journal:  Cancer Chemother Pharmacol       Date:  2019-10-25       Impact factor: 3.333

5.  Targeting EGFR and PI3K pathways in ovarian cancer.

Authors:  S Glaysher; L M Bolton; P Johnson; N Atkey; M Dyson; C Torrance; I A Cree
Journal:  Br J Cancer       Date:  2013-09-10       Impact factor: 7.640

6.  A simple in vitro tumor chemosensitivity assay based on cell penetrating peptide tagged luciferase.

Authors:  Tingyu Yu; Jiao Lin; Jin Zhao; Wei Huang; Lingwen Zeng; Zhiyuan Fang; Ning Xu
Journal:  PLoS One       Date:  2017-11-10       Impact factor: 3.240

7.  Selective vulnerability of ARID1A deficient colon cancer cells to combined radiation and ATR-inhibitor therapy.

Authors:  Shan Xu; Ali Sak; Ben Niedermaier; Yasin Bahadir Erol; Michael Groneberg; Emil Mladenov; MingWei Kang; George Iliakis; Martin Stuschke
Journal:  Front Oncol       Date:  2022-09-30       Impact factor: 5.738

Review 8.  Tumor Chemosensitivity Assays Are Helpful for Personalized Cytotoxic Treatments in Cancer Patients.

Authors:  Engin Ulukaya; Didem Karakas; Konstantinos Dimas
Journal:  Medicina (Kaunas)       Date:  2021-06-19       Impact factor: 2.430

9.  Activity of EGFR, mTOR and PI3K inhibitors in an isogenic breast cell line model.

Authors:  Sharon Glaysher; Louise M Bolton; Penny Johnson; Christopher Torrance; Ian A Cree
Journal:  BMC Res Notes       Date:  2014-06-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.